-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, Zhaoke Ophthalmology-B (06622.HK) announced that on July 13, 2026, the company's innovative drug YUVEZZI™ (2.75% cabacholine and 0.1% bromonidine tartrate eye drops) has been approved by the Macao Special Administrative Region Government Drug Administration for the treatment of presbyopia.

Zhitongcaijing·07/20/2026 04:09:02
Listen to the news
According to Zhitong Finance App, Zhaoke Ophthalmology-B (06622.HK) announced that on July 13, 2026, the company's innovative drug YUVEZZI™ (2.75% cabacholine and 0.1% bromonidine tartrate eye drops) has been approved by the Macao Special Administrative Region Government Drug Administration for the treatment of presbyopia.